Skip to content

Reimbursement for AI in echocardiography is now a reality.

EchoGo® Heart Failure is one of the first AI technologies in echocardiography to move from clinical validation into reimbursed clinical practice, helping healthcare systems integrate AI-powered HFpEF detection into routine care pathways.

FDA-cleared | CPT-supported | Live in leading U.S. hospitals

Reimbursement built into existing care pathways.

Ultromics is building one of the world’s most innovative and trusted AI platforms for cardiovascular disease detection, helping clinicians identify complex heart disease, such as HFpEF and cardiac amyloidosis, early from routine echocardiography.

EchoGo® Heart Failure is supported by CPT code 0932T, enabling AI-assisted HFpEF detection to integrate into established echocardiography billing workflows.

EchoGo® Heart Failure provides augmentative AI-assisted analysis to support physician interpretation and patient management decisions.

The platform analyzes a single apical four-chamber view from routine echocardiography to help identify patients suggestive of HFpEF.

EchoGo® Heart Failure is intended to support clinical interpretation and should not be used as a standalone diagnostic decision-making tool.

Designed around existing echocardiography workflows.

CMS considers EchoGo® Heart Failure a distinct adjunctive stand-alone AI analysis service, separate from the transthoracic echocardiogram (TTE).

Routine transthoracic echocardiography is performed as normal. EchoGo® Heart Failure then provides AI-assisted analysis to support physician interpretation and patient management decisions.

No additional hardware. No new scanning views. No workflow disruption.

Applicable workflows include:

  • Complete transthoracic echocardiography (TTE)
  • Limited or follow-up TTE studies
  • Outpatient cardiovascular imaging
  • Inpatient echocardiography assessment

Reimbursement at a glance

Ultromics is building one of the world’s most innovative and trusted AI platforms for cardiovascular disease detection, helping clinicians identify complex heart disease, such as HFpEF and cardiac amyloidosis, early from routine echocardiography.

  • check_box
    CPT code
    0932T
  • check_box
    Category
    Category III CPT code
  • check_box
    Use
    AI-assisted detection of HFpEF from echocardiography
  • check_box
    National average outpatient reimbursement
    ~$316 per analysis
  • check_box
    Care settings
    Outpatient • Inpatient • Physician office
  • check_box
    Workflow
    Works alongside standard transthoracic echocardiography (TTE)
  • check_box
    Deployment
    No additional scanning protocol required
woman-dancing-red-bg

Hospital outpatient

EchoGo® Heart Failure is reimbursed under the Outpatient Prospective Payment System (OPPS) using CPT code 0932T.

image (28)-1

National average reimbursement

Hospital inpatient

Physician setting

Expanding beyond Medicare pathways.

Reimbursement opportunities may also extend across Medicare Advantage and commercial insurers depending on payer contracts and care setting.

Commercial reimbursement rates may exceed standard Medicare outpatient reimbursement depending on payer agreements and regional contracts.

As healthcare systems increasingly adopt AI-enabled diagnostics, reimbursement pathways continue evolving across cardiovascular care.

The Ultromics difference

Most AI solutions stop at clinical validation.

image (28)-1

Enabling scaled clinical adoption

Ultromics has gone further, working across clinical evidence, regulatory clearance and reimbursement pathways to support real-world adoption at scale

From code to billing

EchoGo® Heart Failure is one of the first AI technologies in echocardiography to move through the full pathway, from code creation to real-world billing.

Paving the way for AI HFpEF reimbursement

Ultromics helped establish the reimbursement pathway for AI-enabled HFpEF detection from echocardiography, supporting real-world deployment across U.S. healthcare systems.

Abstract Data Visualization

Moving beyond AI experimentation

This helps healthcare systems move from AI experimentation toward scalable clinical deployment.

Built to support clinical decision-making.

As with all diagnostic services, reimbursement depends on medical necessity, physician documentation and appropriate clinical use

Supporting clinical indications may include:

  • Shortness of breath
  • Chest discomfort
  • Palpitations
  • Lower extremity edema
  • Syncope or pre-syncope
  • Suspected hypertensive heart disease
  • Other signs suggestive of possible heart failure

EchoGo® Heart Failure supports physician interpretation and should be incorporated within the broader clinical assessment and patient care pathway.

Reimbursement helps accelerate adoption.

EchoGo® Heart Failure was designed to support both clinical and operational value across healthcare systems.

The platform helps support:

  • Earlier HFpEF detection
  • Improved diagnostic confidence
  • Identification of treatable patients
  • Scalable deployment across care settings
  • Clearer operational and reimbursement pathways for adoption

This allows providers to integrate AI-powered cardiovascular detection into routine clinical care with a clearer path toward long-term implementation.



Explore reimbursement pathways with Ultromics.

Speak with our team to learn how EchoGo® Heart Failure fits into clinical workflows, reimbursement pathways and scalable operational deployment.

534518

cases processed